• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Chemother . Epidemiological study using IgM and IgG antibody titers against SARS-CoV-2 in The University of Tokyo, Japan (UT-CATS)

tetano

Editor, Senior Moderator
J Infect Chemother


. 2021 Jun 12;S1341-321X(21)00169-0.
doi: 10.1016/j.jiac.2021.06.008. Online ahead of print.
Epidemiological study using IgM and IgG antibody titers against SARS-CoV-2 in The University of Tokyo, Japan (UT-CATS)


Akihisa Mitani[SUP] 1 [/SUP], Kensuke Hamada[SUP] 2 [/SUP], Naoyuki Yoshikawa[SUP] 3 [/SUP], Yoshifumi Morita[SUP] 3 [/SUP], Takeshi Horie[SUP] 2 [/SUP], Yukiko Inoue[SUP] 2 [/SUP], Minako Saito[SUP] 2 [/SUP], Takashi Ishii[SUP] 2 [/SUP], Mitsuhiro Sunohara[SUP] 2 [/SUP], Ryota Takahashi[SUP] 2 [/SUP], Noriko Emoto[SUP] 2 [/SUP], Nahoko Nishimoto[SUP] 2 [/SUP], Yoko Murano[SUP] 2 [/SUP], Sachiko Okazaki[SUP] 2 [/SUP], Shoko Tateishi[SUP] 2 [/SUP], Atsushi Yao[SUP] 2 [/SUP], Takuya Shimura[SUP] 3 [/SUP], Makoto Kurano[SUP] 3 [/SUP], Yutaka Yatomi[SUP] 3 [/SUP], Shintaro Yanagimoto[SUP] 2 [/SUP]



Affiliations

Abstract

Introduction: The worldwide pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has continued to date. Given that some of the patients with coronavirus disease 2019 (COVID-19) are asymptomatic, antibody tests are useful to determine whether there is a previous infection with SARS-CoV-2. In this study, we measured IgM and IgG antibody titers against SARS-CoV-2 in the serum of asymptomatic healthy subjects in The University of Tokyo, Japan.
Methods: From June 2020, we recruited participants, who were students, staff, and faculty members of The University of Tokyo in the project named The University of Tokyo COVID-19 Antibody Titer Survey (UT-CATS). Following blood sample collection, participants were required to answer an online questionnaire about their social and health information. We measured IgG and IgM titers against SARS-CoV-2 using iFlash-SARS-CoV-2 IgM and IgG detection kit which applies a chemiluminescent immunoassay (CLIA) for the qualitative detection.
Results: There were 6609 volunteers in this study. After setting the cutoff value at 10 AU/mL, 32 (0.48%) were positive for IgG and 16 (0.24%) for IgM. Of six participants with a history of COVID-19, five were positive for IgG, whereas all were negative for IgM. The median titer of IgG was 0.40 AU/mL and 0.39 AU/mL for IgM. Both IgG and IgM titers were affected by gender, age, smoking status, and comorbidities.
Conclusions: Positive rates of IgG and IgM titers were relatively low in our university. Serum levels of these antibodies were affected by several factors, which might affect the clinical course of COVID-19.

Keywords: Antibody titers; Chemiluminescent immunoassay (CLIA); IgG; IgM; Seroepidemiological study; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
 
Back
Top Bottom